CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair
© 2024. The Author(s)..
BACKGROUND: Radiation therapy stands to be one of the primary approaches in the clinical treatment of malignant tumors. Nasopharyngeal Carcinoma, a malignancy predominantly treated with radiation therapy, provides an invaluable model for investigating the mechanisms underlying radiation therapy resistance in cancer. While some reports have suggested the involvement of circRNAs in modulating resistance to radiation therapy, the underpinning mechanisms remain unclear.
METHODS: RT-qPCR and in situ hybridization were used to detect the expression level of circCDYL2 in nasopharyngeal carcinoma tissue samples. The effect of circCDYL2 on radiotherapy resistance in nasopharyngeal carcinoma was demonstrated by in vitro and in vivo functional experiments. The HR-GFP reporter assay determined that circCDYL2 affected homologous recombination repair. RNA pull down, RIP, western blotting, IF, and polysome profiling assays were used to verify that circCDYL2 promoted the translation of RAD51 by binding to EIF3D protein.
RESULTS: We have identified circCDYL2 as highly expressed in nasopharyngeal carcinoma tissues, and it was closely associated with poor prognosis. In vitro and in vivo experiments demonstrate that circCDYL2 plays a pivotal role in promoting radiotherapy resistance in nasopharyngeal carcinoma. Our investigation unveils a specific mechanism by which circCDYL2, acting as a scaffold molecule, recruits eukaryotic translation initiation factor 3 subunit D protein (EIF3D) to the 5'-UTR of RAD51 mRNA, a crucial component of the DNA damage repair pathway to facilitate the initiation of RAD51 translation and enhance homologous recombination repair capability, and ultimately leads to radiotherapy resistance in nasopharyngeal carcinoma.
CONCLUSIONS: These findings establish a novel role of the circCDYL2/EIF3D/RAD51 axis in nasopharyngeal carcinoma radiotherapy resistance. Our work not only sheds light on the underlying molecular mechanism but also highlights the potential of circCDYL2 as a therapeutic sensitization target and a promising prognostic molecular marker for nasopharyngeal carcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Journal of experimental & clinical cancer research : CR - 43(2024), 1 vom: 23. Apr., Seite 122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qu, Hongke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CircCDYL2 |
|---|
| Anmerkungen: |
Date Completed 24.04.2024 Date Revised 07.05.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13046-024-03049-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371432197 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371432197 | ||
| 003 | DE-627 | ||
| 005 | 20240507232603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240424s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13046-024-03049-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1400.xml |
| 035 | |a (DE-627)NLM371432197 | ||
| 035 | |a (NLM)38654320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qu, Hongke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2024 | ||
| 500 | |a Date Revised 07.05.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Radiation therapy stands to be one of the primary approaches in the clinical treatment of malignant tumors. Nasopharyngeal Carcinoma, a malignancy predominantly treated with radiation therapy, provides an invaluable model for investigating the mechanisms underlying radiation therapy resistance in cancer. While some reports have suggested the involvement of circRNAs in modulating resistance to radiation therapy, the underpinning mechanisms remain unclear | ||
| 520 | |a METHODS: RT-qPCR and in situ hybridization were used to detect the expression level of circCDYL2 in nasopharyngeal carcinoma tissue samples. The effect of circCDYL2 on radiotherapy resistance in nasopharyngeal carcinoma was demonstrated by in vitro and in vivo functional experiments. The HR-GFP reporter assay determined that circCDYL2 affected homologous recombination repair. RNA pull down, RIP, western blotting, IF, and polysome profiling assays were used to verify that circCDYL2 promoted the translation of RAD51 by binding to EIF3D protein | ||
| 520 | |a RESULTS: We have identified circCDYL2 as highly expressed in nasopharyngeal carcinoma tissues, and it was closely associated with poor prognosis. In vitro and in vivo experiments demonstrate that circCDYL2 plays a pivotal role in promoting radiotherapy resistance in nasopharyngeal carcinoma. Our investigation unveils a specific mechanism by which circCDYL2, acting as a scaffold molecule, recruits eukaryotic translation initiation factor 3 subunit D protein (EIF3D) to the 5'-UTR of RAD51 mRNA, a crucial component of the DNA damage repair pathway to facilitate the initiation of RAD51 translation and enhance homologous recombination repair capability, and ultimately leads to radiotherapy resistance in nasopharyngeal carcinoma | ||
| 520 | |a CONCLUSIONS: These findings establish a novel role of the circCDYL2/EIF3D/RAD51 axis in nasopharyngeal carcinoma radiotherapy resistance. Our work not only sheds light on the underlying molecular mechanism but also highlights the potential of circCDYL2 as a therapeutic sensitization target and a promising prognostic molecular marker for nasopharyngeal carcinoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Homologous recombination repair | |
| 650 | 4 | |a Nasopharyngeal carcinoma | |
| 650 | 4 | |a RAD51 | |
| 650 | 4 | |a Radiotherapy resistance | |
| 650 | 4 | |a circCDYL2 | |
| 650 | 7 | |a Rad51 Recombinase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 650 | 7 | |a RAD51 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 700 | 1 | |a Wang, Yumin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qijia |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Chunmei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiangyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Can |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Qianjin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fuyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Zhaoyang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of experimental & clinical cancer research : CR |d 1994 |g 43(2024), 1 vom: 23. Apr., Seite 122 |w (DE-627)NLM08283427X |x 1756-9966 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:1 |g day:23 |g month:04 |g pages:122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13046-024-03049-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 1 |b 23 |c 04 |h 122 | ||